KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Restructuring Costs: 2009-2018

Historic Restructuring Costs for Vertex Pharmaceuticals (VRTX) over the last 10 years, with Dec 2018 value amounting to -$184,000.

  • Vertex Pharmaceuticals' Restructuring Costs fell 101.03% to -$4,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $184,000, marking a year-over-year decrease of 98.71%. This contributed to the annual value of -$184,000 for FY2018, which is 101.29% down from last year.
  • According to the latest figures from FY2018, Vertex Pharmaceuticals' Restructuring Costs is -$184,000, which was down 101.29% from $14.2 million recorded in FY2017.
  • Over the past 5 years, Vertex Pharmaceuticals' Restructuring Costs peaked at $50.9 million during FY2014, and registered a low of -$184,000 during FY2018.
  • Over the past 3 years, Vertex Pharmaceuticals' median Restructuring Costs value was $1.3 million (recorded in 2016), while the average stood at $5.1 million.
  • In the last 5 years, Vertex Pharmaceuticals' Restructuring Costs skyrocketed by 1,028.84% in 2017 and then tumbled by 101.29% in 2018.
  • Yearly analysis of 5 years shows Vertex Pharmaceuticals' Restructuring Costs stood at $50.9 million in 2014, then slumped by 95.67% to $2.2 million in 2015, then slumped by 42.79% to $1.3 million in 2016, then soared by 1,028.84% to $14.2 million in 2017, then plummeted by 101.29% to -$184,000 in 2018.